Loading...
•
Dec 31, 2021
Arrowhead Pharmaceuticals Q1 2022 Earnings Report
Arrowhead Pharmaceuticals reported first quarter results for fiscal year 2022.
Key Takeaways
Arrowhead Pharmaceuticals reported its fiscal year 2022 first quarter results with a revenue of $27.439 million and a net loss of $62.872 million, resulting in a net loss per share of $0.60.
Initiated the PALISADE Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome.
Advanced two new investigational candidates that utilize Arrowhead’s pulmonary targeted TRiMTM platform into CTA enabling studies.
Completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI, planned to be the site of a drug manufacturing facility and a laboratory and office facility.
Entered into an exclusive license agreement with GlaxoSmithKline (GSK) under which GSK will develop and commercialize ARO-HSD.
Forward Guidance
Arrowhead Pharmaceuticals did not provide specific financial forward guidance in the press release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...